Search
Now showing items 1-6 of 6
+1040 C/T polymorphism in coding region of thrombin-activatable fibrinolysis inhibitor gene and the risk of idiopathic recurrent fetal loss
(Lippincott Williams & Wilkins, Philadelphia, 2010)
Recurrent fetal loss (RFL) is common health problem affecting up to 5% of women of reproductive age. It has been shown that plasma thrombin-activatable fibrinolysis inhibitor (TAFI) concentrations increase during pregnancy ...
Risk factors for thrombosis in Serbian children
(Lippincott Williams & Wilkins, Philadelphia, 2014)
Venous and arterial thromboses are increasingly encountered in the pediatric population. We present results of a case-control study of inherited and acquired risk factors for thrombosis in 129 pediatric patients from the ...
Early onset of abdominal venous thrombosis in a newborn with homozygous type II heparin-binding site antithrombin deficiency
(Lippincott Williams & Wilkins, Philadelphia, 2017)
The overall incidence of thromboembolic events in the neonatal period is 5 per 100 000 births, wherein more than 40% of all such manifestations are symptomatic renal vein thromboses. We describe the case of a newborn female ...
Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation
(Lippincott Williams & Wilkins, Philadelphia, 2020)
The study was aimed to evaluate the effects of two standard doses of rivaroxaban and dabigatran on global hemostatic assays in patients with atrial fibrillation. The study included 52 patients treated with rivaroxaban ...
The c.-1639G gt A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy
(Lippincott Williams & Wilkins, Philadelphia, 2010)
A single nucleotide polymorphism c.-1639G gt A in the promoter region of vitamin K-epoxide reductase (VKORC1) gene has been found to account for most of the variability in response to oral vitamin K antagonist (VKA). Our ...
Influence of decreased fibrinolytic activity and plasminogen activator inhibitor-1 4G/5G polymorphism on the risk of venous thrombosis
(Lippincott Williams & Wilkins, Philadelphia, 2018)
Objective of our study is to determine whether decreased fibrinolytic activity or plasminogen activator inhibitor (PAI)-1 4G/5G polymorphism influence the risk of venous thrombosis. Our case-control study included 100 ...